May 2 |
Kura Oncology GAAP EPS of -$0.59 misses by $0.03
|
May 2 |
Kura Oncology Reports First Quarter 2024 Financial Results
|
May 1 |
Kura Oncology Q1 2024 Earnings Preview
|
Apr 25 |
Kura Oncology to Report First Quarter 2024 Financial Results
|
Apr 22 |
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
|
Apr 10 |
Kura Oncology to Participate in Stifel Targeted Oncology Forum
|
Mar 10 |
Cantor sees strong year ahead for oncology M&A
|
Mar 6 |
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
|
Feb 28 |
Kura Oncology, Inc. (NASDAQ:KURA) Q4 2023 Earnings Call Transcript
|
Feb 28 |
Q4 2023 Kura Oncology Inc Earnings Call
|